Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | GPR18 | Q14330 | 10/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | SNCA | P37840 | 2/20 | 0.49 |
| ▸ | CNR2 | P34972 | 3/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | CDK4 | P11802 | 1/20 | 0.48 |
| ▸ | CCND1 | P24385 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6258474 | 0.86 | POLB (0.52) | MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL7036257 | 0.82 | TRPA1 (0.47) | MAPTALDH1A1 | |
| SCHEMBL7037571 | 0.82 | HPGD (0.48) | MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL7038057 | 0.82 | MAPT (0.49) | MAPTTDP1ALDH1A1SMN1; SMN2NPSR1 | |
| SCHEMBL6245168 | 0.82 | TRPA1 (0.62) | MAPTALDH1A1SMN1; SMN2NPSR1 | |
| SCHEMBL7036764 | 0.82 | TP53 (0.55) | MAPTTDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL7037451 | 0.81 | TRPA1 (0.54) | MAPTALDH1A1SMN1; SMN2NPSR1NPC1 | |
| SCHEMBL7023804 | 0.81 | TRPA1 (0.54) | MAPTALDH1A1NPSR1RAB9ACNR2 | |
| SCHEMBL7039218 | 0.80 | POLB (0.55) | MEN1MAPTKMT2AALDH1A1NPC1 | |
| SCHEMBL7032494 | 0.80 | CLK1 (0.53) | MEN1MAPTKMT2AALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030004172-A1 | Fused pyrimidinone matrix metalloproteinase inhibitors | HARTER WILLIAM GLEN (US) | 2003-01-02 | — | — | US | claimed |
| US-20030004172-A1 | Fused pyrimidinone matrix metalloproteinase inhibitors | HARTER WILLIAM GLEN (US) | 2003-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004172-A1 | Fused pyrimidinone matrix metalloproteinase inhibitors | MMP13, MMP3, MMP25 | MEN1 3056/4885MAPT 4800/4885KMT2A 1976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.